symbol,statement_type,period_end,line_item,value
TORNTPHARM.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,-68417508.417508
TORNTPHARM.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.285073
TORNTPHARM.NS,income,2025-03-31 00:00:00,Normalized EBITDA,37440000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Total Unusual Items,-240000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-240000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,19110000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,7950000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,27760000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,EBITDA,37200000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,EBIT,29250000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Net Interest Income,-2520000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Interest Expense,2520000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Interest Income,
TORNTPHARM.NS,income,2025-03-31 00:00:00,Normalized Income,19281582491.582493
TORNTPHARM.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,19110000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Total Expenses,83910000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Diluted Average Shares,338409775.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Basic Average Shares,338409775.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Diluted EPS,56.47
TORNTPHARM.NS,income,2025-03-31 00:00:00,Basic EPS,56.47
TORNTPHARM.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,19110000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,19110000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Net Income,19110000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Minority Interests,0.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,19110000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,19110000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Tax Provision,7620000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Pretax Income,26730000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,230000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Special Income Charges,-240000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Other Special Charges,
TORNTPHARM.NS,income,2025-03-31 00:00:00,Impairment Of Capital Assets,
TORNTPHARM.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-2520000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
TORNTPHARM.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,2520000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
TORNTPHARM.NS,income,2025-03-31 00:00:00,Operating Income,29260000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Operating Expense,56150000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Other Operating Expenses,28160000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,7950000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Amortization,
TORNTPHARM.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,7950000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Research And Development,
TORNTPHARM.NS,income,2025-03-31 00:00:00,Selling General And Administration,
TORNTPHARM.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
TORNTPHARM.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
TORNTPHARM.NS,income,2025-03-31 00:00:00,Gross Profit,85410000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Cost Of Revenue,27760000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Total Revenue,113170000000.0
TORNTPHARM.NS,income,2025-03-31 00:00:00,Operating Revenue,113170000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,260408163.265306
TORNTPHARM.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.295918
TORNTPHARM.NS,income,2024-03-31 00:00:00,Normalized EBITDA,34260000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Total Unusual Items,880000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,880000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,16560000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,8080000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,26860000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,EBITDA,35140000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,EBIT,27060000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Net Interest Income,-3540000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Interest Expense,3540000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Interest Income,114800000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Normalized Income,15940408163.265306
TORNTPHARM.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,16560000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Total Expenses,80020000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Diluted Average Shares,338373519.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Basic Average Shares,338373519.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Diluted EPS,48.94
TORNTPHARM.NS,income,2024-03-31 00:00:00,Basic EPS,48.94
TORNTPHARM.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,16560000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,16560000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Net Income,16560000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Minority Interests,0.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,16560000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,16560000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Tax Provision,6960000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Pretax Income,23520000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,580000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Special Income Charges,880000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Other Special Charges,-880000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Impairment Of Capital Assets,129700000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-3540000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,9300000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,3540000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,114800000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Operating Income,25600000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Operating Expense,53160000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Other Operating Expenses,26900000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,8080000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Amortization,5429200000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,8080000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Research And Development,247300000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Selling General And Administration,19019600000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,11296800000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,General And Administrative Expense,7722800000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Gross Profit,78760000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Cost Of Revenue,26860000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Total Revenue,105620000000.0
TORNTPHARM.NS,income,2024-03-31 00:00:00,Operating Revenue,105620000000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,119181630.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.3259
TORNTPHARM.NS,income,2023-03-31 00:00:00,Normalized EBITDA,28448600000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Total Unusual Items,365700000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,365700000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,12452300000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,7020300000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,28276900000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,EBITDA,28814300000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,EBIT,21794000000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Net Interest Income,-3186600000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Interest Expense,3322400000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Interest Income,147800000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Normalized Income,12205781630.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,12452300000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Total Expenses,73236700000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Diluted Average Shares,338445440.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Basic Average Shares,338445440.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Diluted EPS,36.79
TORNTPHARM.NS,income,2023-03-31 00:00:00,Basic EPS,36.79
TORNTPHARM.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,12452300000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,12452300000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Net Income,12452300000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Minority Interests,0.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,12452300000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,12452300000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Tax Provision,6019300000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Pretax Income,18471600000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,73100000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Special Income Charges,170600000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Other Special Charges,-216200000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Impairment Of Capital Assets,45600000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,-3186600000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,12000000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,3322400000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,147800000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Operating Income,21400200000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Operating Expense,44959800000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Other Operating Expenses,5133100000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,7020300000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Amortization,4765600000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,2254700000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Research And Development,312700000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Selling General And Administration,16407500000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,10269900000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,General And Administrative Expense,6137600000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Gross Profit,66360000000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Cost Of Revenue,28276900000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Total Revenue,94636900000.0
TORNTPHARM.NS,income,2023-03-31 00:00:00,Operating Revenue,94636900000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,-1737731400.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.366
TORNTPHARM.NS,income,2022-03-31 00:00:00,Normalized EBITDA,26155600000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Total Unusual Items,-4747900000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-4747900000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,7771800000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,6619300000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,25374700000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,EBITDA,21407700000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,EBIT,14788400000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Net Interest Income,-2479100000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Interest Expense,2529300000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Interest Income,71500000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Normalized Income,10781968600.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,7771800000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Total Expenses,66494600000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Diluted Average Shares,338445440.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Basic Average Shares,338445440.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Diluted EPS,22.96
TORNTPHARM.NS,income,2022-03-31 00:00:00,Basic EPS,22.96
TORNTPHARM.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,7771800000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,7771800000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Net Income,7771800000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Minority Interests,0.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,7771800000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,7771800000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Tax Provision,4487300000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Pretax Income,12259100000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,97300000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Special Income Charges,-4849300000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Other Special Charges,456800000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Impairment Of Capital Assets,4392500000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,-2479100000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,21300000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,2529300000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,71500000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Operating Income,17693400000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Operating Expense,41119900000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Other Operating Expenses,4449200000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,6619300000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Amortization,4157000000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,2462300000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Research And Development,386500000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Selling General And Administration,14397900000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,8849100000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,General And Administrative Expense,5548800000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Gross Profit,58813300000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Cost Of Revenue,25374700000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Total Revenue,84188000000.0
TORNTPHARM.NS,income,2022-03-31 00:00:00,Operating Revenue,84188000000.0
TORNTPHARM.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Total Unusual Items,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
TORNTPHARM.NS,income,2021-03-31 00:00:00,EBITDA,
TORNTPHARM.NS,income,2021-03-31 00:00:00,EBIT,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Net Interest Income,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Interest Expense,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Interest Income,50700000.0
TORNTPHARM.NS,income,2021-03-31 00:00:00,Normalized Income,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Total Expenses,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Diluted Average Shares,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Basic Average Shares,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Diluted EPS,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Basic EPS,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Net Income,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Minority Interests,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Tax Provision,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Pretax Income,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Special Income Charges,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Other Special Charges,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Impairment Of Capital Assets,4800000.0
TORNTPHARM.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,21200000.0
TORNTPHARM.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,50700000.0
TORNTPHARM.NS,income,2021-03-31 00:00:00,Operating Income,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Operating Expense,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Amortization,4206000000.0
TORNTPHARM.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Research And Development,251800000.0
TORNTPHARM.NS,income,2021-03-31 00:00:00,Selling General And Administration,13082900000.0
TORNTPHARM.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,7426300000.0
TORNTPHARM.NS,income,2021-03-31 00:00:00,General And Administrative Expense,5656600000.0
TORNTPHARM.NS,income,2021-03-31 00:00:00,Gross Profit,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Total Revenue,
TORNTPHARM.NS,income,2021-03-31 00:00:00,Operating Revenue,
